Advertisement

Topics

Targovax Company Profile

15:31 EDT 21st September 2018 | BioPortfolio

Targovax was started in October 2010 to develop TG01, a vaccine targeting pancreatic cancer. TG01 is based on research from The Radium Hospital and Norsk Hydro in the end of the 90’s. The drug has already been tested in patients, and the company is building on these results. The company is based in Lysaker close to Oslo, Norway, and co-located with Oslo Cancer Cluster.


News Articles [28 Associated News Articles listed on BioPortfolio]

Is Targovax going to be the next big game changer in the Immuno-Oncology field?

Targovax and Oncos Therapetics have recently joined forces to provide a combination treatment in the Immuno-Oncology field. Targovax brings with it a clinical stage peptide vaccine and Oncos Therapeu...

Targovax (TRVX) - FOLFIRINOX sets bar in pancreatic cancer high

Edison Investment Research - Pharmaceutical & healthcare - Targovax: On 12 June, Targovax announced a strategic decision to move away from developing TG01, a neoantigen cancer vaccine for pancreatic c...

Targovax doses first patient in ONCOS-102 and DCVAC Phase I/II trial

Targovax, along with SOTIO, has dosed the first patient in a Phase I/II clinical trial investigating the safety and immune...Read More... The post Targovax doses first patient in ONCOS-102 and DCVAC P...

Targovax Adjusts Clinical Pipeline After ASCO Disrupts TG Vaccine Program

Targovax terminates development of TG01 in pancreatic cancer patients after data unveiled at ASCO fundamentally alters development preconditions for its...   

Targovax gives pipeline update

Targovax strengthens management team with appointment of CFO

Targovax (TRVX) - Key catalysts in 2018

Edison Investment Research - Pharmaceutical & healthcare - Targovax: Q417 saw the release of several reports indicating a good safety profile and consistent immune activation signs by ONCOS-102, an on...

Norwegian Pancreatic Cancer Vaccine Drastically Improves Survival

Targovax has obtained positive Phase I/II results showing its pancreatic cancer vaccine improved the survival of 32 patients also receiving chemotherapy over two years. Targovax, based in Oslo, Norway...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Targovax

Targovax was started in October 2010 to develop TG01, a vaccine targeting pancreatic cancer. TG01 is based on research from The Radium Hospital and Norsk Hydro in the end of the 9...

More Information about "Targovax" on BioPortfolio

We have published hundreds of Targovax news stories on BioPortfolio along with dozens of Targovax Clinical Trials and PubMed Articles about Targovax for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Targovax Companies in our database. You can also find out about relevant Targovax Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record